The SEP-363856 MDD study is a phase 2/3, randomized, double-blind, placebo-controlled study to evaluate an investigational drug in adults diagnosed with major depressive disorder (MDD) who are currently depressed and have used an antidepressant medication without sufficient improvement in their depression symptoms. The investigational drug is an oral medication that is taken daily along with an approved antidepressant treatment for 14 weeks.

Who is eligible to participate in this study?

To pre-qualify for this study, you must:

      -Be 18 to 65 years of age
      -Have been diagnosed with MDD and currently are experiencing a depressive episode
      -Have used at least 1 but not more than 3 antidepressant medications in your current depressive episode
       without sufficient improvement in your depression symptoms

Additional criteria will apply. All study-related visits, tests, and drugs will be provided at no cost. You may also be reimbursed for study-related travel expenses.

For more information or participate in this study, please fill out the form below and our staff will contact you in 24-48 hours. 

Join a Study

If you are interested in learning more or participating in any of our studies, please fill out the form below and our office will get back to you within 1-2 business days. 

*By signing up you agree to be contacted about clinical research studies by our company, its affiliates or partners. Typical methods of contact include phone calls, text messages, pre-recorded messages, emails, automated technology or postal mail. This includes if the number is currently on any Do Not Call Lists. As we contact you, your electronic record will be updated accordingly with current relevant health information. This consent is not required to participate in a clinical research study.